6.3.1.9 (Z)-8-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-7-(2-hydroxy-3-phenoxy propyl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione 88.5% activity remaining 224694 6.3.1.9 1,3,5-trimethyl-N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]-1H-pyrazole-4-sulfonamide - 192538 6.3.1.9 1,4,7-trioxo-1lambda5,4lambda5,7lambda5-benzo[1,2-c:3,4-c':5,6-c'']tris[1,2,5]oxadiazole 64.4% activity remaining 222912 6.3.1.9 1-(1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-5-(4-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 83.5% activity remaining 222916 6.3.1.9 1-(1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-5-(4-fluorophenyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 83.5% activity remaining 222917 6.3.1.9 1-(1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-5-(4-fluorophenyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 90.8% activity remaining 222917 6.3.1.9 1-(3-(1-isobutyl-1H-pyrazol-4-yl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192582 6.3.1.9 1-(3-(1H-indol-4-yl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192583 6.3.1.9 1-(3-(3-chlorophenyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192584 6.3.1.9 1-(3-(3-fluorophenyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192585 6.3.1.9 1-(3-(3-pyridyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192586 6.3.1.9 1-(3-(4-chlorophenyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192587 6.3.1.9 1-(3-(furan-2-yl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192588 6.3.1.9 1-(3-phenyl-1H-indazol-1-yl)-3,3-dimethylbutan-2-one - 192601 6.3.1.9 1-(5-(3,5-dichlorophenyl)-2H-tetrazol-2-yl)-3,3-dimethylbutan-2-one - 192625 6.3.1.9 1-(5-(3,5-dichlorophenyl)-2H-tetrazol-2-yl)butan-2-one - 192626 6.3.1.9 1-(5-(3,5-dichlorophenyl)-2H-tetrazol-2-yl)propan-2-one - 192627 6.3.1.9 1-(5-(3,5-difluorophenyl)-2H-tetrazol-2-yl)-3,3-dimethylbutan-2-one - 192628 6.3.1.9 1-(5-(3-fluorophenyl)-2H-tetrazol-2-yl)-3,3-dimethylbutan-2-one - 192629 6.3.1.9 1-(6-chloro-1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-5-(4-hydroxy-3-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 85.3% activity remaining 222936 6.3.1.9 1-(6-chloro-1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-5-(4-hydroxy-3-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 97.4% activity remaining 222936 6.3.1.9 1-(6-chloro-1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-5-(4-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 82.1% activity remaining 222937 6.3.1.9 1-(6-chloro-1,3-benzothiazol-2-yl)-4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-5-(4-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 98.7% activity remaining 222937 6.3.1.9 1-(6-chloro-1,3-benzothiazol-2-yl)-4-(3,4-dimethoxybenzoyl)-5-(4-fluorophenyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 66.0% activity remaining 222938 6.3.1.9 1-(6-chloro-1,3-benzothiazol-2-yl)-4-(3,4-dimethoxybenzoyl)-5-(4-fluorophenyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 99.6% activity remaining 222938 6.3.1.9 1-(tert-butylsulfonylmethyl)-3-(3-fluorophenyl)-1H-indazole - 192655 6.3.1.9 1-[3-(3-fluorophenyl)-1H-indazol-1-yl]-3,3-dimethylbutan-2-one i.e. DDD85811, inhibits growth of bloodstream Trypanosoma brucei in vitro 78428 6.3.1.9 1-[5-(3-chloro-4-methylphenyl)-2H-tetrazol-2-yl]-3,3-dimethylbutan-2-one - 192707 6.3.1.9 2,4-dimethyl-N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]-1,3-thiazole-5-sulfonamide - 192720 6.3.1.9 2,4-dimethyl-N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]thiophene-3-sulfonamide - 192721 6.3.1.9 2,6-dichloro-N-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzenesulfonamide - 192724 6.3.1.9 2,6-dichloro-N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]benzenesulfonamide - 192725 6.3.1.9 2,6-difluoro-N-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzenesulfonamide - 192726 6.3.1.9 2,6-dimethoxy-N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]benzenesulfonamide - 192727 6.3.1.9 2-((tert-butylsulfonyl)methyl)-4-(2-fluorophenyl)thiazole - 192728 6.3.1.9 2-((tert-butylsulfonyl)methyl)-4-(2-methylphenyl)thiazole - 192729 6.3.1.9 2-((tert-butylsulfonyl)methyl)-4-(3-chlorophenyl)thiazole - 192730 6.3.1.9 2-((tert-butylsulfonyl)methyl)-4-(3-methoxyphenyl)thiazole - 192731 6.3.1.9 2-((tert-butylsulfonyl)methyl)-4-(phenyl)thiazole - 192732 6.3.1.9 2-(3-(3-fluorophenyl)-1H-indazol-1-yl)-1-(piperidin-1-yl)ethanone - 192740 6.3.1.9 2-(3-(3-fluorophenyl)-1H-indazol-1-yl)-N,N-dimethylacetamide - 192741 6.3.1.9 2-(3-(3-fluorophenyl)-1H-indazol-1-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)acetamide - 192742 6.3.1.9 2-(3-(3-fluorophenyl)-1H-indazol-1-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide - 192743 6.3.1.9 2-(5-(3,5-dichlorophenyl)-2H-tetrazol-2-yl)-N,N-dimethylacetamide - 192752 6.3.1.9 2-(5-(3,5-difluorophenyl)-2H-tetrazol-2-yl)-1-phenylethanone - 192753 6.3.1.9 2-(9-bromo-3-chloro-6-oxo-7,12-dihydroindolo[3,2-d][1]benzazepin-5(6H)-yl)-N-[2-(methylamino)ethyl]acetamide - 223065 6.3.1.9 2-(9-bromo-3-chloro-6-oxo-7,12-dihydroindolo[3,2-d][1]benzazepin-5(6H)-yl)-N-[2-(methylamino)ethyl]acetamide 59.0% activity remaining 223065 6.3.1.9 2-(9-bromo-3-chloro-6-oxo-7,12-dihydroindolo[3,2-d][1]benzazepin-5(6H)-yl)-N-[2-(methylamino)ethyl]acetamide 55.5% activity remaining 223065 6.3.1.9 2-(tert-butylsulfonylmethyl)-4-(3-trifluoromethylphenyl)thiazole - 192759 6.3.1.9 2-methyl-N-((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)propane-2-sulfonamide - 192781 6.3.1.9 2-[3-(3-fluorophenyl)-1H-indazol-1-yl]-1-(piperidin-1-yl)ethanone i.e. DDD86243, inhibits growth of bloodstream Trypanosoma brucei in vitro. Exposure to DDD86243 at 2 x EC50 for 72 h decreases intracellular trypanothione levels to less than 10% of wild type, with a corresponding 5fold increase in the precursor metabolite, glutathione 78429 6.3.1.9 3,3-dimethyl-1-(3-(1-methyl-1H-indol-4-yl)-1H-indazol-1-yl)butan-2-one - 192844 6.3.1.9 3,3-dimethyl-1-(3-(naphthalen-2-yl)-1H-indazol-1-yl)butan-2-one - 192845 6.3.1.9 3,3-dimethyl-1-(3-(pyridin-4-yl)-1H-indazol-1-yl)butan-2-one - 192846 6.3.1.9 3,3-dimethyl-1-(3-(thiophen-3-yl)-1H-indazol-1-yl)butan-2-one - 192847 6.3.1.9 3,3-dimethyl-1-(5-phenyl-2H-tetrazol-2-yl)butan-2-one - 192848 6.3.1.9 3,3-dimethyl-1-[5-[3-(trifluoromethyl)phenyl]-2H-tetrazol-2-yl]butan-2-one - 192849 6.3.1.9 3,3-dimethyl-1-[5-[4-(trifluoromethyl)phenyl]-2H-tetrazol-2-yl]butan-2-one - 192850 6.3.1.9 3,5-dichloro-N-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzenesulfonamide - 192851 6.3.1.9 3-((3-(3-fluorophenyl)-1H-indazol-1-yl)methyl)-5-methylisoxazole - 192853 6.3.1.9 3-((3-(3-fluorophenyl)-1H-indazol-1-yl)methyl)-5-phenylisoxazole - 192854 6.3.1.9 3-(3-fluorophenyl)-1-(pyridin-2-ylmethyl)-1H-indazole - 192858 6.3.1.9 3-(3-fluorophenyl)-1-(pyridin-3-ylmethyl)-1H-indazole - 192859 6.3.1.9 3-(tert-butylsulfonylmethyl)-1-(3-fluorophenyl)-1H-indazole - 192869 6.3.1.9 3-(tert-butylsulfonylmethyl)-1-phenyl-1H-indazole - 192870 6.3.1.9 4-((3-(3-fluorophenyl)-1H-indazol-1-yl)methyl)-2,5-dimethyloxazole - 192901 6.3.1.9 4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-1-(6-methoxy-1,3-benzothiazol-2-yl)-5-(4-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 77.9% activity remaining 223326 6.3.1.9 4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-1-(6-methoxy-1,3-benzothiazol-2-yl)-5-(4-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one 97.6% activity remaining 223326 6.3.1.9 4-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)-3-hydroxy-5-(4-methoxyphenyl)-1-(6-methyl-1,3-benzothiazol-2-yl)-1,5-dihydro-2H-pyrrol-2-one 83.9% activity remaining 223327 6.3.1.9 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid above 100 mM 118748 6.3.1.9 4-acetyl-N-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzenesulfonamide - 192955 6.3.1.9 4-methoxy-N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]benzenesulfonamide - 192961 6.3.1.9 4-methoxy-N-[[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]benzenesulfonamide - 192962 6.3.1.9 4-methyl-N-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzenesulfonamide - 192963 6.3.1.9 5-oxo-1H,3H-5lambda5-benzo[1,2-c:4,5-c']bis[1,2,5]oxadiazole - 223560 6.3.1.9 5-oxo-1H,3H-5lambda5-benzo[1,2-c:4,5-c']bis[1,2,5]oxadiazole 7.3% activity remaining 223560 6.3.1.9 5-oxo-1H,3H-5lambda5-benzo[1,2-c:4,5-c']bis[1,2,5]oxadiazole 63.5% activity remaining 223560 6.3.1.9 6-fluoro-3-oxo-4,5-didehydro-2,1,3lambda5-benzoxadiazole 84.1% activity remaining 223581 6.3.1.9 ammonium sulfate almost complete inhibition at 500 mM 1058 6.3.1.9 betulin competitive inhibition 9522 6.3.1.9 buthionine sulfoximine - 2076 6.3.1.9 conessine competitive allosteric inhibition 194596 6.3.1.9 DL-(S,R)-buthionine sulfoximine DL-(S,R)-BSO, a multitarget inhibitor of trypanothione synthesis, in vivo effects on nonthiol-supplied epimastigote cells, on Cys-supplied epimastigote cells, and on GSH-supplied epimastigote cells, overview. Inhibition of gamma-glutamylcysteine synthetase and trypanothione synthetase. Wild-type Trypanosoma brucei cells are not restored by supplementing with 0.08 mM GSH. The the L-(S,R)-BSO stereoisomer is more potent that the the D-(S,R)-BSO. Inhibitor docking analysis, binding structure 224695 6.3.1.9 glutathione substrate inhibition 44 6.3.1.9 GSH substrate inhibition 142 6.3.1.9 KCl approx. 50% inhibition at 500 mM 79 6.3.1.9 megazol - 57907 6.3.1.9 Melarsen oxide - 3825 6.3.1.9 methyl (3-phenyl-1H-indazol-1-yl)acetate - 193234 6.3.1.9 additional information the enzyme mediates resistance to H2O2 and organic hyperoxids, and to trypanocidic drugs 2 6.3.1.9 additional information limited proteolysis with trypsin or factor Xa result in cleavage of wild-type and mutant enzymes at R553 followed by loss of activity, cleavage of wild-type and mutant R553Q can be delayed by presence of substrates 2 6.3.1.9 additional information synthesis and inhibitory potencies of indazole analogue inhibitors, overview 2 6.3.1.9 additional information screening of different scaffold-derived compounds for inhibitory activity on enzyme TryS, overview. No inhibition by [3-[4-([6-(3,4-dimethoxyphenyl)-7-[(ethylcarbamothioyl)amino]pyrido[2,3-d]pyrimidin-2-yl]amino)phenyl]propyl]molybdenum(1+) and 1,4,7-trioxo-1lambda5,4lambda5,7lambda5-benzo[1,2-c:3,4-c':5,6-c'']tris[1,2,5]oxadiazole 2 6.3.1.9 additional information screening of different scaffold-derived compounds for inhibitory activity on enzyme TryS, overview. No effect by 8-[(2E)-2-[(2,4-dihydroxyphenyl)methylidene]hydrazinyl]-7-(2-hydroxy-3-phenoxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione and J31 2 6.3.1.9 additional information screening of different scaffold-derived compounds for inhibitory activity on enzyme TryS, overview 2 6.3.1.9 N,N'-[6-(2,5-dichlorophenyl)pyrido[2,3-d]pyrimidine-2,7-diyl]bis(N'-tert-butylurea) - 223886 6.3.1.9 N,N'-[6-(2,5-dichlorophenyl)pyrido[2,3-d]pyrimidine-2,7-diyl]bis(N'-tert-butylurea) 24.3% activity remaining 223886 6.3.1.9 N,N'-[6-(2,5-dichlorophenyl)pyrido[2,3-d]pyrimidine-2,7-diyl]bis(N'-tert-butylurea) 61.3% activity remaining 223886 6.3.1.9 N,N'-[6-(2H-1,3-benzodioxol-5-yl)pyrido[2,3-d]pyrimidine-2,7-diyl]bis(N'-tert-butylurea) - 223887 6.3.1.9 N,N'-[6-(2H-1,3-benzodioxol-5-yl)pyrido[2,3-d]pyrimidine-2,7-diyl]bis(N'-tert-butylurea) 25.3% activity remaining 223887 6.3.1.9 N,N'-[6-(2H-1,3-benzodioxol-5-yl)pyrido[2,3-d]pyrimidine-2,7-diyl]bis(N'-tert-butylurea) 52.2% activity remaining 223887 6.3.1.9 N,N-dibenzyl-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193240 6.3.1.9 N,N-diethyl-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide - 193242 6.3.1.9 N,N-diethyl-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide - 193243 6.3.1.9 N-(1-phenylethyl)-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193250 6.3.1.9 N-(2-(dimethylamino)ethyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide - 193253 6.3.1.9 N-(2-methoxyethyl)-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193256 6.3.1.9 N-(2-phenylethyl)-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193257 6.3.1.9 N-(3-(1H-imidazol-1-yl)propyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide - 193258 6.3.1.9 N-(3-(dimethylamino)propyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide - 193259 6.3.1.9 N-(4-chlorobenzyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide - 193270 6.3.1.9 N-(4-chlorobenzyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1Hindazol-1-yl)acetamide - 193271 6.3.1.9 N-(4-[methyl[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]sulfamoyl]phenyl)acetamide - 193274 6.3.1.9 N-(4-[[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]sulfamoyl]phenyl)acetamide - 193275 6.3.1.9 N-(butan-2-yl)-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193279 6.3.1.9 N-(thiophen-2-ylmethyl)-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193283 6.3.1.9 N-cyclohexyl-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193296 6.3.1.9 N-methyl-(3-(dimethylamino)propyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide - 193301 6.3.1.9 N-phenyl-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193305 6.3.1.9 N-propyl-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]acetamide - 193306 6.3.1.9 N-[(2-phenyl-1,3-thiazol-4-yl)methyl]naphthalene-2-sulfonamide - 193309 6.3.1.9 N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]benzenesulfonamide - 193311 6.3.1.9 N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]naphthalene-1-sulfonamide - 193337 6.3.1.9 N-[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]thiophene-2-sulfonamide - 193338 6.3.1.9 N-[2-(methylamino)ethyl]-2-[6-oxo-9-(trifluoromethyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-5(6H)-yl]acetamide i.e. FS-554, N5-substituted paullone 224029 6.3.1.9 N-[2-(methylamino)ethyl]-2-[6-oxo-9-(trifluoromethyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-5(6H)-yl]acetamide i.e. FS-554 224029 6.3.1.9 N-[2-(methylamino)ethyl]-2-[6-oxo-9-(trifluoromethyl)-7,12-dihydroindolo[3,2-d][1]benzazepin-5(6H)-yl]acetamide i.e. FS-554, 40.5% activity remaining 224029 6.3.1.9 N-[2-amino-6-(2H-1,3-benzodioxol-5-yl)pyrido[2,3-d]pyrimidin-7-yl]-N'-ethylthiourea - 224034 6.3.1.9 N-[2-amino-6-(2H-1,3-benzodioxol-5-yl)pyrido[2,3-d]pyrimidin-7-yl]-N'-ethylthiourea 20.9% activity remaining 224034 6.3.1.9 N-[2-amino-6-(2H-1,3-benzodioxol-5-yl)pyrido[2,3-d]pyrimidin-7-yl]-N'-ethylthiourea 65.4% activity remaining 224034 6.3.1.9 N-[2-amino-6-(naphthalen-2-yl)pyrido[2,3-d]pyrimidin-7-yl]-N'-tert-butylurea - 224038 6.3.1.9 N-[2-amino-6-(naphthalen-2-yl)pyrido[2,3-d]pyrimidin-7-yl]-N'-tert-butylurea 48.7% activity remaining 224038 6.3.1.9 N-[2-amino-6-(naphthalen-2-yl)pyrido[2,3-d]pyrimidin-7-yl]-N'-tert-butylurea 32.3% activity remaining 224038 6.3.1.9 N-[4-([[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]sulfamoyl)phenyl]acetamide - 193358 6.3.1.9 N-[4-([[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]sulfamoyl)phenyl]acetamide - 193359 6.3.1.9 N-[[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]benzenesulfonamide - 193361 6.3.1.9 N-[[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]benzenesulfonamide - 193362 6.3.1.9 N1,N10-bis[[4-(propan-2-yl)phenyl]methyl]decane-1,10-diamine - 224081 6.3.1.9 N1,N10-bis[[4-(propan-2-yl)phenyl]methyl]decane-1,10-diamine 51.1% activity remaining 224081 6.3.1.9 N1,N10-bis[[4-(propan-2-yl)phenyl]methyl]decane-1,10-diamine 53.5% activity remaining 224081 6.3.1.9 N1,N12-bis[(4-bromophenyl)methyl]dodecane-1,12-diamine - 224082 6.3.1.9 N1,N12-bis[(4-bromophenyl)methyl]dodecane-1,12-diamine 47.5% activity remaining 224082 6.3.1.9 N1,N12-bis[(4-bromophenyl)methyl]dodecane-1,12-diamine 30.8% activity remaining 224082 6.3.1.9 N1,N12-bis[(4-chlorophenyl)methyl]dodecane-1,12-diamine - 224083 6.3.1.9 N1,N12-bis[(4-chlorophenyl)methyl]dodecane-1,12-diamine 42.4% activity remaining 224083 6.3.1.9 N1,N12-bis[(4-chlorophenyl)methyl]dodecane-1,12-diamine 23.8% activity remaining 224083 6.3.1.9 N1,N3-bis[(4-methoxyphenyl)methyl]propane-1,3-diamine - 224084 6.3.1.9 N1,N4-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]butane-1,4-diamine - 224085 6.3.1.9 N1,N4-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]butane-1,4-diamine 50.9% activity remaining 224085 6.3.1.9 N1,N4-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]butane-1,4-diamine 25.6% activity remaining 224085 6.3.1.9 N1,N4-bis[[4-(benzyloxy)phenyl]methyl]butane-1,4-diamine - 224086 6.3.1.9 N1,N4-bis[[4-(benzyloxy)phenyl]methyl]butane-1,4-diamine 37.9% activity remaining 224086 6.3.1.9 N1,N4-bis[[4-(benzyloxy)phenyl]methyl]butane-1,4-diamine 26.6% activity remaining 224086 6.3.1.9 N1,N6-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]hexane-1,6-diamine - 224087 6.3.1.9 N1,N6-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]hexane-1,6-diamine 61.2% activity remaining 224087 6.3.1.9 N1,N6-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]hexane-1,6-diamine 17.0% activity remaining 224087 6.3.1.9 N1,N6-bis[[4-(benzyloxy)phenyl]methyl]hexane-1,6-diamine - 224088 6.3.1.9 N1,N6-bis[[4-(benzyloxy)phenyl]methyl]hexane-1,6-diamine 48.9% activity remaining 224088 6.3.1.9 N1,N6-bis[[4-(benzyloxy)phenyl]methyl]hexane-1,6-diamine 33.4% activity remaining 224088 6.3.1.9 N1,N8-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]octane-1,8-diamine - 224089 6.3.1.9 N1,N8-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]octane-1,8-diamine 55.6% activity remaining 224089 6.3.1.9 N1,N8-bis[[4-(benzyloxy)-3-methoxyphenyl]methyl]octane-1,8-diamine 28.9% activity remaining 224089 6.3.1.9 nifurtimox - 3221 6.3.1.9 Pentamidine - 2216 6.3.1.9 prochlorperazine inhibitor DDD66604, binding mode and structure, overview 9603 6.3.1.9 tert-butyl-4-(2-(2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamido)ethyl)piperazine-1-carboxylate - 193379 6.3.1.9 tomatine competitive inhibition versus spermidine, uncompetitive inhibition with respect to ATP and GSH 194595 6.3.1.9 triostam - 32741 6.3.1.9 trypanothione competitive feedback inhibition 1726 6.3.1.9 uvaol competitive allosteric inhibition 71562 6.3.1.9 [3-[4-([6-(3,4-dimethoxyphenyl)-7-[(ethylcarbamothioyl)amino]pyrido[2,3-d]pyrimidin-2-yl]amino)phenyl]propyl]molybdenum(1+) 81.3% activity remaining 224216